This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (32)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Topic Collections  • Dermatology, Other  • Alert me on articles by topic  Social Bookmarking   What's this?

Theodor Karamfilov, MD; Helga Konrad, MD; Kerstin Karte, MD; Uwe Wollina, MD

Arch Dermatol. 2000;136:487-490.

Background  Primary focal hyperhidrosis is a common condition that gives rise to functional and emotional problems and may disturb professional and social life. Recently, low-dose intracutaneous injections of botulinum toxin A have been shown to induce a temporary anhidrosis, with relapses occurring usually after 4 to 6 months.

Objective  To evaluate the short- and long-term effectiveness and possible adverse effects of high-dose botulinum toxin therapy in the treatment of axillary hyperhidrosis.

Design  In an open study, patients with focal hyperhidrosis were treated with intracutaneous injections of botulinum toxin A (Botox; Allergan Inc, Irvine, Calif). A total dose of 200 U of botulinum toxin A was used once per axilla. Patients were observed for up to 15 months.

Settings  University medical center.

Patients  Twenty-four patients with axillary hyperhidrosis were treated. Their ages ranged from 19 to 58 years (mean ± SD, 34.8 ± 12.4 years).

Main Outcome Measures  Reduction of sweating as assessed by the Minor iodine-starch test and planimetry of hyperhidrotic areas. Patients were interviewed at the end of follow-up about their satisfaction with this treatment.

Results  Within 6 days, all patients reported cessation of excessive sweating. The mean ± SD area of excessive sweating identified by the Minor iodine-starch test decreased from 19.27 ± 11.95 cm² to 0.25 ± 0.61 cm² (P<.001). The mean follow-up was 10.0 ± 2.8 months (range, 5-15 months). Four patients (17%) reported a return of axillary hyperhidrosis after 7 to 10 months. All patients who experienced relapse showed an excellent response to a second treatment. The only adverse effects reported were temporary pain and burning during the injections. No muscular weakness, insensitivity, or systemic reactions were observed.

Conclusions  High-dose botulinum toxin A seems to be as safe as low-dose botulinum toxin A in the treatment of axillary hyperhidrosis. The preliminary data suggest a lower rate of relapse.

From the Department of Dermatology, the Friedrich Schiller University of Jena, Jena, Germany.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Low-Dose Efficacy of Botulinum Toxin A for Axillary Hyperhidrosis: A Randomized, Side-By-Side, Open-Label Study
Heckmann et al.
Arch Dermatol 2005;141:1255-1259.
ABSTRACT | FULL TEXT  

Experiences in Thoracoscopic Sympathectomy for Axillary Hyperhidrosis and Osmidrosis: Focusing on the Extent of Sympathectomy
Hsu et al.
Arch Surg 2001;136:1115-1117.
ABSTRACT | FULL TEXT  

Evaluation of Therapeutic Success of Hyperhidrosis Therapy
Heckmann et al.
Arch Dermatol 2001;137:94-94.
FULL TEXT  

High-Dose Botulinum Toxin Type A for Axillary Hyperhidrosis
Schnider et al.
Arch Dermatol 2000;136:1567-1567.
FULL TEXT  

Botulinum Toxin: Beyond Cosmesis
Klein and Glogau
Arch Dermatol 2000;136:539-541.
FULL TEXT